Pharmaceuticals company Wockhardt announced Q4FY24 & FY24 results: YoY growth of 7% in revenue in FY24, Revenue for FY24 of Rs 2,879 crore compared to Rs 2,693 crore in the previous year. QoQ growth of 6%, Revenue for the quarter being Rs 750 crore compared to Rs 710 crore in Q4FY23. YoY growth of 74% in EBITDA in FY24, EBITDA for FY24 at Rs 251 crore compared to Rs 144 crore in the previous year. Quarterly growth in EBITDA by 49% compared to the previous year, EBITDA for Q4FY24 at Rs 70 crore compared to Rs 47 crore in Q4FY23. UK Business stood at Rs 268 crore in Q4FY24 compared to Rs 242 crore in Q4FY23 registering a growth of 11% and contributed about 36% of Global Revenue in the current quarter. UK Business stood at Rs 1,041 crore in FY24 compared to Rs 887 crore in FY23 registering a growth of 17% and contributed about 36% of Global Revenue in FY24. Emerging Markets Business of the Company stood at Rs 190 crore in Q4FY24 contributing to about 25% of the Global Revenue. Emerging Markets Business stood at Rs 642 crore in FY24 compared to Rs 555 crore in FY23 registering a growth of 16% and contributing to about 22% of the Global Revenue. Irish Business stood at Rs 45 crore in Q4FY24 compared to Rs 44 crore in Q4FY23 registering a growth of 4%. Irish Business stood at Rs 179 crore in FY24 compared to Rs 158 crore in FY23 registering a growth of 13%. India Business stood at Rs 181 crore in Q4FY24 compared to Rs 125 crore in the previous year registering a growth of 45%. India business stood at Rs 641 crore compared to Rs 609 crore in FY23 registering a growth of 5% and contributing to 22% of the Global Revenue in FY24. US Business stood at Rs 42 crore in Q4FY24 contributing 6% of the Global Revenue. US Business stood at Rs 175 crore in FY24 contributing 6% of the Global Revenue. Result PDF